In an optimistic outlook at the 43rd JPM Conference in San Francisco, Thermo Fisher CEO Marc Casper underscored the firm's strategic adaptations and growth initiatives tailored to meet surging demand for GLP-1 diabetes and weight loss products. Thermo Fisher Scientific's extensive investment in its
The contract development and manufacturing organization (CDMO) industry has seen significant advancements and partnerships as of January 2025. With a focus on large molecules and advanced therapies, this article delves into the latest developments, highlighting key trends, common themes, and
The Blood and Cell Advocacy Register (BCAR) is a newly launched consortium that aims to revolutionize the development and commercialization of advanced therapy medicinal products (ATMPs). Formed in December 2024, BCAR brings together experts and organizations from the blood and cell industries to
In a groundbreaking partnership aimed at revolutionizing the production processes for stem cell-based therapies, Mytos has joined forces with Aspen Neuroscience to enhance the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs). These cells are integral to Aspen’s ANPD001, an
CAR-T cell therapy has emerged as a groundbreaking approach in cancer treatment, leveraging the body's immune system to target and destroy cancer cells. Since its inception in 2017, this innovative therapy has rapidly evolved, with numerous products reaching commercialization and receiving
The pharmaceutical and biotechnology sectors are witnessing a whirlwind of significant developments, from legal disputes over acquisition terms to pivotal personnel changes and strategic restructuring initiatives. These shifts are emblematic of an industry in constant evolution, driven by
